Auditory Neuropathy Spectrum Disorder: Genetic and Electrophysiological Testing for Predicting Rehabilitation Outcomes after Cochlear Implantation

Reviling the etiology or at least pathophysiology of auditory neuropathy spectrum disorder is crucial for choosing rehabilitation pathway and predicting rehabilitation outcomes. Some patients with auditory neuropathy spectrum disorder undergo cochlear implantation, but it is not always possible to foresee the results of rehabilitation. Genetic testing, especially in cases without obviously perinatal hearing loss risk factors, might help to understand etiology and pathophysiology, whether it is synaptopathy or neuropathy; therefore, it becomes possible to predict rehabilitation outcomes. More than 20 genes related to auditory neuropathy spectrum disorder phenotype are known already. Modern genetic approaches, such as whole genome and whole exome sequencing, reveal etiology of auditory neuropathy spectrum disorder in many cases. But there are still auditory neuropathy spectrum disorder cases with unknown etiology and site of the lesion. Electrophysiological methods (electrocochleography, electrically evoked brainstem potentials) might help to localize the site of lesion in hearing system and therefore help to predict rehabilitation outcomes. Electrically evoked brainstem potential testing after cochlear implantation seems to be applicable and useable tool to predict potential CI outcomes and to choose optimal rehabilitation trace

Audiological Evidence of Frequent Hereditary Mild, Moderate and Moderate-to-Severe Hearing Loss

Congenital and early onset bilateral sensorineural hearing loss (SNHL) is mainly caused by mutations in numerous genes. The introduction of universal newborn hearing screening (UNHS) has increased the number of infants with mild, moderate, and moderate-to-severe sensorineural hearing loss (SNHL) detected in the first year of life. We aimed to evaluate the audiological features in patients with mild, moderate, and moderate-to-severe SNHL according to genotype. Audiological and genetic data were analyzed for 251 patients and their relatives with congenital bilateral mild, moderate, and moderate-to-severe SNHL. Hearing loss severity, audiogram profile, interaural symmetry, and dynamics of hearing thresholds were analyzed. In this case, 165 patients had GJB2 gene mutations, 30 patients were identified with STRC mutations, and 16 patients had pathogenic or likely pathogenic USH2A mutations. The presence of at least one GJB2 non-truncating variant in genotype led to less severe hearing impairment. The flat and gently sloping audiogram profiles were mostly revealed in all groups. The follow-up revealed the stability of hearing thresholds. GJB2, STRC, and USH2A pathogenic variants were detected in most patients in our cohort and were congenital in most cases

Spectrum of Genes for Non-GJB2-Related Non-Syndromic Hearing Loss in the Russian Population Revealed by a Targeted Deafness Gene Panel

Hearing loss is one of the most genetically heterogeneous disorders known. Over 120 genes are reportedly associated with non-syndromic hearing loss (NSHL). To date, in Russia, there have been relatively few studies that apply massive parallel sequencing (MPS) methods to elucidate the genetic factors underlying non-GJB2-related hearing loss cases. The current study is intended to provide an understanding of the mutation spectrum in non-GJB2-related hearing loss in a cohort of Russian sensorineural NSHL patients and establish the best diagnostic algorithm. Genetic testing using an MPS panel, which included 33 NSHL and syndromic hearing loss (SHL) genes that might be misdiagnosed as NSHL genes, was completed on 226 sequentially accrued and unrelated patients. As a result, the molecular basis of deafness was found in 21% of the non-GJB2 NSHL cases. The total contribution pathogenic, and likely pathogenic, variants in the genes studied among all hereditary NSHL Russian patients was 12%. STRC pathogenic and likely pathogenic, variants accounted for 30% of diagnoses in GJB2-negative patients, providing the most common diagnosis. The majority of causative mutations in STRC involved large copy number variants (CNVs) (80%). Among the point mutations, the most common were c.11864G>A (p.Trp3955*) in the USH2A gene, c.2171_2174delTTTG (p.Val724Glyfs*6) in the STRC gene, and c.107A>C (p.His36Pro) and c.1001G>T (p.Gly334Val) in the SLC26A4 gene. Pathogenic variants in genes involved in SHL accounted for almost half of the cases with an established molecular genetic diagnosis, which were 10% of the total cohort of patients with non-GJB2-related hearing loss